What do the 2011 American heart association guidelines tell us about prevention of cardiovascular disease in women?

Clinical Cardiology

Volumn 34, Issue 9, 2011, Pages 520-523

  Wenger, Nanette K ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ABDOMINAL AORTA ANEURYSM; AMERICAN HEART ASSOCIATION CARDIOVASCULAR DISEASE PREVENTION GUIDELINE FOR WOMEN; ANGINA PECTORIS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BLOOD PRESSURE; BODY MASS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CIGARETTE SMOKING; DEPRESSION INVENTORY; DIABETES MELLITUS; DIET; DIET RESTRICTION; DIETARY INTAKE; DRUG CONTRAINDICATION; DYSLIPIDEMIA; EXERCISE; FAMILY HISTORY; FASTING BLOOD GLUCOSE; FRAMINGHAM RISK SCORE; FRUIT; GLUCOSE BLOOD LEVEL; HEALTH BEHAVIOR; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART REHABILITATION; HIGH FIBER DIET; HIGH RISK POPULATION; HUMAN; HYPERTENSION; IMMOBILIZATION; ISCHEMIC HEART DISEASE; LABORATORY TEST; LIFESTYLE MODIFICATION; MATERNAL HYPERTENSION; MEDICAL HISTORY; MEDICAL SOCIETY; METABOLIC SYNDROME X; MOTIVATION; MUSCLE TRAINING; OBESITY; PAROXYSMAL HEART ATRIUM FIBRILLATION; PATIENT COMPLIANCE; PATIENT EDUCATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSICAL ACTIVITY; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PREECLAMPSIA; PREGNANCY DIABETES MELLITUS; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SMOKING CESSATION; VEGETABLE; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

AMERICAN HEART ASSOCIATION; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; LIFE STYLE; PATIENT COMPLIANCE; PATIENT EDUCATION AS TOPIC; PRACTICE GUIDELINES AS TOPIC; PREVENTIVE MEDICINE; RISK ASSESSMENT; SEX FACTORS; UNITED STATES; WOMEN'S HEALTH;

EID: 80052741708     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20940     Document Type: Review

References (33)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2011 update: a report from the American Heart Association [published correction appears in Circulation. 2011;123:e240]. Circulation. 2011; 123: e18-e209.
2. Gholizadeh L, Davidson P., More similarities than differences: an international comparison of CVD mortality and risk factors in women. Health Care Women Int. 2008; 29: 3-22.
3. Mosca L, Mochari-Greenberger H, Dolor RJ, et al. Twelve-year follow-up of American women's awareness of cardiovascular disease risk and barriers to heart health. Circ Cardiovasc Qual Outcomes. 2010; 3: 120-127.
4. Kleindorfer D, Khoury J, Broderick JP, et al. Temporal trends in public awareness of stroke: warning signs, risk factors, and treatment. Stroke. 2009; 40: 2502-2506.
5. Ferris A, Robertson RM, Fabunmi R, et al. for American Heart Association, American Stroke Association. American Heart Association and American Stroke Association national survey of stroke risk awareness among women. Circulation. 2005; 111: 1321-1326. (Pubitemid 40389098)
6. Doroochi H, Abdolrasulnia M, Foster JA, et al. Knowledge and attitudes of primary care physicians in the management of patients at risk for cardiovascular events. BMC Fam Pract. 2008; 9: 42.
7. Barnhart J, Lewis V, Houghton JL, et al. Physician knowledge levels and barriers to coronary risk prevention in women: survey results from the Women and Heart Disease Physician Education Initiative. Womens Health Issues. 2007; 17: 93-100. (Pubitemid 46509734)
8. Francke AL, Smit MC, de Veer AJ, et al. Factors influencing the implementation of clinical guidelines for health care professionals: a systematic meta-review. BMC Med Inform Decis Mak. 2008; 8: 38.
9. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the American Heart Association. Circulation. 2011; 123: 1243-1262.
10. Hsia J, Rodabough RJ, Manson JE, et al. for the Women's Health Initiative Research Group. Evaluation of the American Heart Association cardiovascular disease prevention guideline for women. Circ Cardiovasc Qual Outcomes. 2010; 3: 128-134.
11. Salmon JE, Roman MJ., Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med. 2008; 121 (suppl 1): S3-S8.
12. Wilson BJ, Watson MS, Prescott GJ, et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ. 2003; 326: 845-849. (Pubitemid 36461414)
13. Ray JG, Vermeulen MJ, Schull MJ, et al. Cardiovascular Health After Maternal Placental Syndromes (CHAMPS): population-based retrospective cohort study. Lancet. 2005; 366: 1797-1803. (Pubitemid 41642644)
14. Bellamy L, Casas JP, Hingorani AD, et al. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007; 335: 974-985.
15. Banerjee M, Cruickshank JK., Pregnancy as the prodrome to vascular dysfunction and cardiovascular risk. Nat Clin Pract Cardiovasc Med. 2006; 3: 596-603. (Pubitemid 44614921)
16. Garovic VD, Hayman SR., Hypertension in pregnancy: an emerging risk factor for cardiovascular disease. Nat Clin Pract Nephrol. 2007; 3: 613-622. (Pubitemid 350012820)
17. Sattar N., Do pregnancy complications and CVD share common antecedents? Atheroscler Suppl. 2004; 5: 3-7. (Pubitemid 38581785)
18. Lloyd-Jones DM, Hong Y, Labarthe D, et al. on behalf of the American Heart Association Strategic Planning Task Force and Statistics Committee. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's Strategic Impact Goal through 2020 and beyond. Circulation. 2010; 121: 586-613.
19. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010; 122: e584-e636.
20. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005; 352: 1293-1304.
21. Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006; 295; 306-313.
22. Wann LS, Curtis AB, January CT, et al. for ACCF/AHA Task Force Members. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011; 123: 104-123.
23. Snow V, Barry P, Fihn SD, et al. for the American College of Physicians/American College of Cardiology Chronic Stable Angina Panel. Primary care management of chronic stable angina and asymptomatic suspected or known coronary artery disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2004; 141: 562-567. (Pubitemid 39350247)
24. Dagenais GR, Pogue J, Fox K, et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet. 2006; 368: 581-588. (Pubitemid 44209181)
25. Pitt B, Remme W, Zannad F, et al. for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348: 1309-1321. (Pubitemid 36384098)
26. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA. 2002; 288: 321-333.
27. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative Randomized Controlled Trial. JAMA. 2004; 291; 1701-1712.
28. Heiss G, Wallace R, Anderson GL, et al. for the WHI Investigators. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA. 2008; 299; 1036-1045. (Pubitemid 351347060)
29. Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005; 294: 56-65. (Pubitemid 41002839)
30. Cook NR, Albert CM, Gaziano JM, et al. A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study. Arch Intern Med. 2007; 167: 1610-1618. (Pubitemid 47280341)
31. BÃnaa KH, NjÃlstad I, Ueland PM, et al. for NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006; 354: 1578-1588.
32. Lewis WR, Ellrodt AG, Peterson E, et al. Trends in the use of evidence-based treatments for coronary artery disease among women and the elderly: findings from the Get With the Guidelines Quality-Improvement Program. Circ Cardiovasc Qual Outcomes. 2009; 2: 633-641.
33. Kok G, van den Borne B, Mullen PD., Effectiveness of health education and health promotion: meta-analyses of effect studies and determinants of effectiveness. Patient Educ Couns. 1997; 30: 19-27. (Pubitemid 27077203)